Mitotech S.A.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 24, 2027The maintenance fee for Oral formulations of mitochondrially-targeted antioxidants and their preparation and use (US 9,192,676) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Pharmaceutical substances on the basis of mitochondria-addressed antioxidants (US 9,233,903) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
- 1 fee due Oct 12, 2027The maintenance fee for Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations (US 9,308,214) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,349,902 | Pharmaceutical compositions useful for preventing and treating oncological diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,233,903 | Pharmaceutical substances on the basis of mitochondria-addressed antioxidants In force · From the USPTO record | In force | From the USPTO record | |
| US 9,308,214 | Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations In force · From the USPTO record | In force | From the USPTO record | |
| US 9,427,444 | Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages In force · From the USPTO record | In force | From the USPTO record | |
| US 9,192,676 | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,572,890 | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,188,669 | Mitochondria-Targeted Antioxidants for Treatment of Age-Related Brain Disorders In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 7: 4 patents in force now held by others · 5 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 9 no status recorded